AgomAb Therapeutics News and Activities

Acquisition, funding and merger involving AgomAb Therapeutics.

• AgomAb Therapeutics has just announced a $89 Million fundraising (posted on October 29 2024).

View the org chart displaying its 12 main executives

Most searched biographies at AgomAb Therapeutics

• Tim Knotnerus, Chief Executive Officer and Director
• Felice Verduyn-Van Weegen, Director
• Ohad Hammer, Director

Create your alert
to follow the executive moves at AgomAb Therapeutics.

AgomAb Therapeutics has 2,418 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Sequana Medical has filed for bankruptcy protection  (posted on June 30 2026).
• Zymeworks has announced the acquisition of Theravance Biopharma  (posted on June 29 2026).
• Tissium has just announced a $68 Million fundraising (posted on June 29 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by AgomAb Therapeutics

• News & Events – Agomab Therapeutics
• Agomab in the news – Agomab Therapeutics
• News & Events – AgomAb Therapeutics

Social media about AgomAb Therapeutics

• AgomAb Therapeutics on Wikipedia, Google News & Yahoo Finance
• AgomAb Therapeutics on LinkedIn, X (Twitter) & YouTube